Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek® National Conference
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the acceptance of two scientific abstracts at the PAINWeek® 2020 National Conference which will take place virtually September 11-13, 2020.
Details of the poster presentations are as follows:
For additional information, including the full abstracts, please visit the PAINWeek® 2020 National Conference website: https://www.painweek.org/conferences/painweek/live-virtual-conference
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018, Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com.
SOURCE Neurana Pharmaceuticals, Inc.